---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-005468"
form_type: "8-K"
ticker: "OPK"
cik: "0000944809"
company_name: "OPKO HEALTH, INC."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T03:00:27.029340+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# OPKO Health reports Q4 net income of $14M, revenue $183.6M; BARDA/Merck milestones boost pharma

## Summary
- Consolidated Q4 revenue $183.6M vs $181.9M; net income $14.0M ($0.01 diluted EPS) vs net loss of $66.5M in Q4 2023.
- Pharma segment operating loss narrowed to $2.1M from $16.0M; IP transfer revenue rose to $43.1M (includes $12.5M Merck milestone, $23.8M BARDA).
- Diagnostics revenue fell to $103.1M from $124.2M on asset sales; operating loss improved to $21.7M from $42.3M.
- BARDA awarded additional $51M for COVID/influenza antibodies; total awards to ModeX now $110M, up to $205M if all options exercised.
- Capital actions: repurchased $17M principal notes, 10.9M shares for $16.5M; reduced share count 10% in 2024; sold part of BioReference for $237.5M.

## SEC filing metadata
- accession: 0001437749-25-005468
- form_type: 8-K
- ticker: OPK
- cik: 0000944809
- company_name: OPKO HEALTH, INC.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/944809/000143774925005468/0001437749-25-005468-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/944809/000143774925005468/opk20250103_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-005468
- JSON: https://secwatch.observer/filing/0001437749-25-005468.json
- Plain text: https://secwatch.observer/filing/0001437749-25-005468.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.